CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients

被引:0
|
作者
Stephens, Dustin B. [1 ]
de Leon, Jose [2 ]
机构
[1] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA
[2] Univ Kentucky, Coll Med, Dept Psychiat, Lexington, KY 40506 USA
关键词
CYP2D6; cytochrome P450; phenotype; self-harm; suicide; ultra-rapid; metabolizer; AMPLICHIP CYP450 TEST; CYP2C19; GENOTYPES; SEROTONIN; IMPACT; PHARMACOGENETICS; DEBRISOQUINE; BRAIN; PERSONALITY; ANTIDEPRESSANTS; POLYMORPHISM;
D O I
10.2217/pgs-2016-0086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: Suicide accounts for over 800,000 deaths per year worldwide and is the tenth leading cause of mortality in USA. Several studies have investigated cytochrome P450 CYP2D6 ultra-rapid metabolizer (UM) phenotype in relation to suicidality, with mixed results. This study tested the hypothesis of increased suicide risk among CYP2D6 UMs. Patients & methods: Among the 4264 state psychiatric hospital inpatients included, 2435 (57%) reported a prior suicide attempt. Results: No association between UM status and attempted suicide was observed in bivariate (odds ratio: 0.87; 95% Cl: 0.531.25), multivariate (adjusted odds ratio: 0.89; 95% Cl: 0.55-1.46), or risk-stratified analyses. Conclusion: These results contrast with prior reports of increased suicidality among CYP2D6 UMs and highlight the pressing need to identify reliable screening methods to better address this persistent public health problem.
引用
收藏
页码:1295 / 1304
页数:10
相关论文
共 50 条
  • [31] Rapid detection of the intermediate metabolizer associated CYP2D6 polymorphisms*9 and*17 with real time PCR
    Steimer, W
    Müller, T
    Popp, J
    Heres, S
    Kissling, W
    Leucht, S
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 242 - 243
  • [32] CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
    Ivanov, Hristo Y.
    Grigorova, Denitsa
    Lauschke, Volker M.
    Velinov, Branimir
    Stoychev, Kaloyan
    Kyosovska, Gergana
    Shopov, Peter
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (07):
  • [33] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [34] Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
    Raimundo, S
    Fischer, R
    Eichelbaum, M
    Griese, EU
    Schwab, M
    Zanger, UM
    PHARMACOGENETICS, 2000, 10 (07): : 577 - 581
  • [35] Serum Concentrations of Risperidone and Aripiprazole in Subgroups Encoding CYP2D6 Intermediate Metabolizer Phenotype
    Hendset, Magnhild
    Molden, Espen
    Knape, Magnus
    Hermann, Monica
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 80 - 85
  • [36] Poor CYP2D6 and ultrarapid CYP2C19 metabolizer: Clinical challenge in psychiatric treatment
    Dlugauskas, E.
    Lengvenyte, A.
    Strumila, R.
    Utkus, A.
    EUROPEAN PSYCHIATRY, 2017, 41 : S163 - S163
  • [37] Slow CYP2D6 metabolizer phenotype associated with death in a toddler receiving a therapeutic dose of dextromethorphan. 313
    Benoit Bailey
    Nick Daneman
    Richard Daneman
    Joel M Mayer
    Gideon Koren
    Pediatric Research, 1997, 41 (Suppl 4) : 55 - 55
  • [38] CYP2D6, serotonin and suicide
    Ahlner, Johan
    Zackrisson, Anna-Lena
    Lindblom, Bertil
    Bertilsson, Leif
    PHARMACOGENOMICS, 2010, 11 (07) : 903 - 905
  • [39] MAJOR INFLUENCE OF THE CYP2D6*41 ALLELE ON CYP2D6 METABOLIZER PHENOTYPE - A STUDY ON 1,021 VENLAFAXINE-TREATED PATIENTS
    Haslemo, T.
    Eliasson, E.
    Jukic, M.
    Ingelman-Sundberg, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 8 - 8
  • [40] CYP2D6 metabolizer status and postoperative analgesia with tramadol
    Wilder-Smith, CH
    Wilkins, J
    ANESTHESIOLOGY, 1999, 91 (3A) : U416 - U416